Medicare Benefits Schedule - Item 73336

Search Results for Item 73336

Category 6 - PATHOLOGY SERVICES

73336

73336 - Additional Information

Item Start Date:
01-Dec-2013
Description Updated:
01-Apr-2020
Schedule Fee Updated:
01-Dec-2013

Group
P7 - Genetics

A test of tumour tissue from a patient with stage III or stage IV metastatic cutaneous melanoma, requested by, or on behalf of, a specialist or consultant physician, to determine if the requirements relating to BRAF V600 mutation status for access to dabrafenib, vemurafenib or encorafenib under the Pharmaceutical Benefits Scheme are fulfilled.

Fee: $230.95 Benefit: 75% = $173.25 85% = $196.35


Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change